BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 21352589)

  • 1. The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Chau NG; Perez-Ordonez B; Zhang K; Pham NA; Ho J; Zhang T; Ludkovski O; Wang L; Chen EX; Tsao MS; Kamel-Reid S; Siu LL
    Head Neck Oncol; 2011 Feb; 3():11. PubMed ID: 21352589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma.
    Nakano T; Yamamoto H; Nakashima T; Nishijima T; Satoh M; Hatanaka Y; Shiratsuchi H; Yasumatsu R; Toh S; Komune S; Oda Y
    Hum Pathol; 2016 Apr; 50():51-61. PubMed ID: 26997438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial.
    Vermorken JB; Psyrri A; Mesía R; Peyrade F; Beier F; de Blas B; Celik I; Licitra L
    Ann Oncol; 2014 Apr; 25(4):801-807. PubMed ID: 24577117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relationship between human papilloma virus infection and expression of p16 and EGFR in head and neck squamous cell carcinoma and their prognostic significance].
    Ma L; Wang D; Wufuer A; Wu R; Zhang S; Wang R
    Zhonghua Zhong Liu Za Zhi; 2014 Jan; 36(1):23-8. PubMed ID: 24685082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-Met expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation.
    Baschnagel AM; Williams L; Hanna A; Chen PY; Krauss DJ; Pruetz BL; Akervall J; Wilson GD
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):701-7. PubMed ID: 24521684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype.
    Rampias T; Pectasides E; Prasad M; Sasaki C; Gouveris P; Dimou A; Kountourakis P; Perisanidis C; Burtness B; Zaramboukas T; Rimm D; Fountzilas G; Psyrri A
    Ann Oncol; 2013 Aug; 24(8):2124-31. PubMed ID: 23406730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma.
    Husain H; Psyrri A; Markovic A; Rampias T; Pectasides E; Wang H; Slebos R; Yarbrough WG; Burtness B; Chung CH
    Laryngoscope; 2012 Dec; 122(12):2762-8. PubMed ID: 23086695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of p16 in locally advanced squamous cell carcinoma of the head and neck treated with concurrent cisplatin and radiotherapy.
    Lau HY; Brar S; Klimowicz AC; Petrillo SK; Hao D; Brockton NT; Kong CS; Lees-Miller SP; Magliocco AM
    Head Neck; 2011 Feb; 33(2):251-6. PubMed ID: 20848448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
    Licitra L; Mesia R; Rivera F; Remenár É; Hitt R; Erfán J; Rottey S; Kawecki A; Zabolotnyy D; Benasso M; Störkel S; Senger S; Stroh C; Vermorken JB
    Ann Oncol; 2011 May; 22(5):1078-1087. PubMed ID: 21048039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular biology of squamous cell carcinoma of the head and neck: relevance and therapeutic implications.
    Schmitz S; Machiels JP
    Expert Rev Anticancer Ther; 2010 Sep; 10(9):1471-84. PubMed ID: 20836682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined CD44, c-MET, and EGFR expression in p16-positive and p16-negative head and neck squamous cell carcinomas.
    Baschnagel AM; Tonlaar N; Eskandari M; Kumar T; Williams L; Hanna A; Pruetz BL; Wilson GD
    J Oral Pathol Med; 2017 Mar; 46(3):208-213. PubMed ID: 27442811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
    Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer.
    Pajares B; Trigo JM; Toledo MD; Álvarez M; González-Hermoso C; Rueda A; Medina JA; de Luque V; Jerez JM; Alba E
    BMC Cancer; 2013 Jan; 13():26. PubMed ID: 23331666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p16, HPV, and Cetuximab: What Is the Evidence?
    Bonner JA; Mesia R; Giralt J; Psyrri A; Keilholz U; Rosenthal DI; Beier F; Schulten J; Vermorken JB
    Oncologist; 2017 Jul; 22(7):811-822. PubMed ID: 28526718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas.
    Kong CS; Narasimhan B; Cao H; Kwok S; Erickson JP; Koong A; Pourmand N; Le QT
    Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):553-61. PubMed ID: 19427557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma.
    Young RJ; Rischin D; Fisher R; McArthur GA; Fox SB; Peters LJ; Corry J; Lim A; Waldeck K; Solomon B
    Cancer Epidemiol Biomarkers Prev; 2011 Jun; 20(6):1230-7. PubMed ID: 21467228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPV-associated p16 INK4A expression and response to therapy and survival in selected head and neck cancers.
    Kanyilmaz G; Ekinci O; Muge A; Celik S; Ozturk F
    Asian Pac J Cancer Prev; 2015; 16(1):253-8. PubMed ID: 25640361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Chung CH; Lee JW; Slebos RJ; Howard JD; Perez J; Kang H; Fertig EJ; Considine M; Gilbert J; Murphy BA; Nallur S; Paranjape T; Jordan RC; Garcia J; Burtness B; Forastiere AA; Weidhaas JB
    Ann Oncol; 2014 Nov; 25(11):2230-2236. PubMed ID: 25081901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency and prognostic significance of p16(INK4A) protein overexpression and transcriptionally active human papillomavirus infection in laryngeal squamous cell carcinoma.
    Young RJ; Urban D; Angel C; Corry J; Lyons B; Vallance N; Kleid S; Iseli TA; Solomon B; Rischin D
    Br J Cancer; 2015 Mar; 112(6):1098-104. PubMed ID: 25688737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.